Smartphone-controlled Optogenetically Engineered Cells Enable Semiautomatic Glucose Homeostasis in Diabetic Mice

Jiawei Shao,Shuai Xue,Guiling Yu,Yuanhuan Yu,Xueping Yang,Yu Bai,Sucheng Zhu,Linfeng Yang,Jianli Yin,Yidan Wang,Shuyong Liao,Sanwei Guo,Mingqi Xie,Martin Fussenegger,Haifeng Ye
DOI: https://doi.org/10.1126/scitranslmed.aal2298
IF: 17.1
2017-01-01
Science Translational Medicine
Abstract:With the increasingly dominant role of smartphones in our lives, mobile health care systems integrating advanced point-of-care technologies to manage chronic diseases are gaining attention. Using a multidisciplinary design principle coupling electrical engineering, software development, and synthetic biology, we have engineered a technological infrastructure enabling the smartphone-assisted semiautomatic treatment of diabetes in mice. A custom-designed home server SmartController was programmed to process wireless signals, enabling a smartphone to regulate hormone production by optically engineered cells implanted in diabetic mice via a far-red light (FRL)-responsive optogenetic interface. To develop this wireless controller network, we designed and implanted hydrogel capsules carrying both engineered cells and wirelessly powered FRL LEDs (light-emitting diodes). In vivo production of a short variant of human glucagon-like peptide 1 (shGLP-1) or mouse insulin by the engineered cells in the hydrogel could be remotely controlled by smartphone programs or a custom-engineered Bluetooth-active glucometer in a semiautomatic, glucose-dependent manner. By combining electronic device-generated digital signals with optogenetically engineered cells, this study provides a step toward translating cell-based therapies into the clinic.
What problem does this paper attempt to address?